It is important to increase both patient and provider awareness about these new treatments so that patients with high risk of severe disease can be able to access them.Rebecca Wang, MD
As we hit the two-year mark of the COVID-19 pandemic in the United States, it appears that the pandemic may finally be transitioning to an endemic phase. The “new normal” healthcare providers envision includes diagnostic tests and oral medications being readily available for the community, with an overall goal of increasing access to life-saving treatments that need to be given quickly to be effective.
On the latest episode of Dartmouth-Hitchcock Health’s (D-HH) “The Cure Podcast,” infectious disease physician Rebecca Wang, MD, and medical co-director of the comprehensive antimicrobial program, and Craig P. Worby, PharmD, BCIDP, BCCCP, BCPS, an infectious disease clinical pharmacist, joined host Jose R. Mercado, MD, D-HH COVID-19 Response Leader, to discuss two currently available outpatient COVID-19 therapies, Paxlovid and Molnupiravir.
Listen to episode 17 of “The Cure Podcast” HERE
“We are in a very different place now with COVID-19 treatments than we were even a couple of months ago,” Wang said. “There are several new outpatient treatment options for treatment of COVID-19 that have received emergency use authorization by the Food and Drug Administration, all of which have proven efficacy in decreasing risk of hospitalization or death. The two agents that we discussed today can be taken by mouth, taking away a layer of complexity to their administration. And while supply for all these agents does remain limited, they are increasing, particularly as new diagnoses of COVID-19 have been falling nationally. It is important to increase both patient and provider awareness about these new treatments so that patients with high risk of severe disease can be able to access them."
For more information from D-HH on COVID-19, click here.
Subscribe to “The Cure” wherever you get your podcasts. Visit “The Cure” webpage for all episodes.
DARTMOUTH-HITCHCOCK HEALTH (D-HH), New Hampshire’s only academic health system and the state’s largest private employer, serves a population of 1.9 million across Northern New England. D-H provides access to more than 2,400 providers in almost every area of medicine, delivering care at its flagship hospital, Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, NH. DHMC was named in 2019 as the #1 hospital in New Hampshire by U.S. News & World Report, and recognized for high performance in 13 clinical specialties and procedures. Dartmouth-Hitchcock Health also includes the Norris Cotton Cancer Center, one of only 51 NCI-designated Comprehensive Cancer Centers in the nation; the Children's Hospital at Dartmouth-Hitchcock, the state’s only children’s hospital; affiliated member hospitals in Lebanon, Keene, and New London, NH, and Windsor, VT, and Visiting Nurse and Hospice for Vermont and New Hampshire; and 24 Dartmouth-Hitchcock clinics that provide ambulatory services across New Hampshire and Vermont. The D-H system trains nearly 400 residents and fellows annually, and performs world-class research, in partnership with the Geisel School of Medicine at Dartmouth and the White River Junction VA Medical Center in White River Junction, VT.